HYDROmorphone Injectable Syringes Recalled Due to Unvalidated Sanitization Cycles
Central Admixture Pharmacy is recalling HYDROmorphone injection syringes nationwide due to lack of validated sanitization cycles, which compromises sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II injectable drug recall for unvalidated sanitization cycles that could compromise product sterility. No illnesses or injuries reported in the source text. Hazard is theoretical, not based on confirmed contamination, so the severity is High rather than Severe.
Plain-English summary
Central Admixture Pharmacy Services Inc is recalling HYDROmorphone in Dextrose 5%, 0.5 mg/5 mL, 5 mL syringes due to lack of assurance of sterility. The recall involves 1,389 syringes with lot numbers and expiration dates ranging from July to September 2023.
The recall is prompted by lack of validation data for sanitization cycles. Injectable pharmaceutical products must be manufactured under sterile conditions, and without validated sanitization procedures, the product's sterility cannot be assured.
The affected product was distributed nationwide in the United States. Patients and healthcare facilities in possession of affected lots should contact Central Admixture Pharmacy Services Inc or the FDA for guidance on proper handling and disposal of the recalled product.
The recalled product
- Product
- HYDROmorphone in Dextrose 5%, 0.5 mg/5 mL (0.1 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2013-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable
- Hazard
- sterility-defect
- validation-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot: 17-270683
- Exp 7/18/2023
- 17-271119
- Exp 7/25/2023
- 17-271339
- Exp 7/27/2023
- 17-272202
- Exp 8/10/2023
- 17-272241
- Exp 8/13/2023
- 17-272783
- Exp 8/22/2023
- 17-273431
- Exp 9/3/2023
- 17-273615
- Exp 9/5/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27